Key Highlights

  • Silexion Therapeutics activated its first clinical site for a Phase 2/3 pancreatic cancer trial of SIL204 on July 29, 2026, but held just $2.2 million in cash at June 30, 2026.
  • Context Therapeutics reported a 29% response rate among evaluable platinum-resistant ovarian cancer patients in its Phase 1a CTIM-76 trial, with cash of $43.0 million expected to fund operations into Q4 2027.
  • Silexion completed a 1-for-10 reverse split in May 2026 and closed a $2.5 million public offering in August, saying it believes it has regained Nasdaq stockholders'-equity compliance.
  • Context dosed the first patient in a Phase 1 trial of CT-202, a second bispecific candidate, on September 9, 2026, after discontinuing an earlier program.

Cancer Drug Development costs a lot, takes years and fails often, and small companies in the field can look alike from the outside. Silexion Therapeutics (NASDAQ:SLXN) and Context Therapeutics (NASDAQ:CNTX) are both Nasdaq-listed oncology developers, but they approach cancer in different ways. Silexion is developing an RNA interference therapy aimed at KRAS-mutated tumors, while Context is developing bispecific antibodies that direct T cells to attack solid tumors.

Silexion Therapeutics (NASDAQ:SLXN): Starting a Pancreatic Cancer Trial on Limited Cash

Silexion develops RNAi treatments for cancers driven by mutations in the KRAS gene, a target that has long been hard to drug. Its lead candidate, SIL204, is being tested in a Phase 2/3 program in locally advanced pancreatic cancer. The company has approvals from Israel's Ministry of Health and Germany's BfArM. In an August 14, 2026 update, Silexion said its first clinical site, Tel Aviv Sourasky Medical Center, had been activated on July 29 and that it expected to dose the first patient soon after, with more Israeli and German sites to follow. The company also reported preclinical data suggesting that SIL204 may make tumor cells more visible to the immune system across four KRAS mutations, supporting possible combinations with checkpoint inhibitors.

The company has very little cash. For the six months ended June 30, 2026, Silexion reported a net loss of $6.3 million, about 50% higher than a year earlier, including roughly $3.6 million in the second quarter. Research and Development spending more than doubled to $3.6 million. Cash was $2.2 million at June 30. The company completed a 1-for-10 reverse split on May 28, 2026, and closed a public offering with gross proceeds of about $2.5 million on August 13, 2026. After that offering, Silexion said it believes it has regained compliance with Nasdaq's $2.5 million stockholders' Equity requirement. Its filings still include going-concern language.

Context Therapeutics (NASDAQ:CNTX): Early Clinical Data and a Larger Cash Balance

Context Therapeutics develops T-cell-engaging bispecific antibodies for solid tumors. Its lead candidate, CTIM-76, targets Claudin 6, a protein found in some ovarian, testicular and endometrial cancers. In June 2026, Context reported interim Phase 1a data on 21 treated patients. Among seven evaluable patients with platinum-resistant ovarian cancer who received active doses, two had responses, for a 29% response rate, and four had disease control; these patients had received a median of seven prior lines of therapy. Cytokine release syndrome occurred in 11% of those patients and was limited to Grade 1. CTIM-76 received FDA Fast Track Designation in April 2026. The sample is very small, and the results are early.

Context has narrowed its pipeline. It discontinued CT-95 and, on September 9, 2026, dosed the first patient in a Phase 1 trial of CT-202, a Nectin-4 x CD3 bispecific antibody, in urothelial, colorectal and triple-negative breast cancers. For the second quarter of 2026, Context reported a net loss of $14.6 million, compared with $8.8 million a year earlier, and cash of $43.0 million. It expects that cash to fund operations into the fourth quarter of 2027. Upcoming catalysts include a Phase 1b expansion of CTIM-76 in the first quarter of 2027, data from every-three-week dosing in the second quarter of 2027, and initial CT-202 data in the second half of 2027.

What Cancer Biotech Investors Should Examine

These two companies are at different stages. Context has human efficacy and safety data, an FDA designation and a cash runway it has stated. Silexion has regulatory clearances and preclinical data, but the new trial has only begun enrolling patients and the company has little cash for a Phase 2/3 program.

  • Evidence stage: How much of each company's case depends on human data versus preclinical or earlier-generation results?
  • Sample size: Will CTIM-76 response rates hold up as more patients are treated and dosing changes?
  • Runway versus milestones: Does the cash last until the next data readout? Context guides into Q4 2027, while Silexion had $2.2 million at June 30 plus the August raise.
  • Share structure: How have reverse splits, offerings and warrants changed the share count?

Using the Nasdaq Composite as a Benchmark

The Nasdaq Composite covers a wide range of companies, giving investors a reference point for the market as a whole. Comparing each stock's return with the index over the same period can show whether a move came from market sentiment or from company events such as data releases, financings or reverse splits.

The index is used here only as a comparison benchmark, not as a claim that either stock is a member. Context announced in July 2026 that it had been added to the Russell 2000, a separate small-cap index.

Risks

For Silexion, the main risk is financing. The company must fund a multi-country Phase 2/3 trial with a very small cash balance, which will probably require more equity raises. It has also completed a reverse split in 2026 and only recently regained compliance with Nasdaq's equity rule.

Context's main risks are clinical. Early response rates in small groups often fall as trials grow, and T-cell engagers can cause immune-related side effects. Quarterly spending of about $14.6 million will require more Capital beyond late 2027 unless a Partnership or other funding arrives.

Cash Runway and Evidence Quality Separate These Two Stories

Silexion and Context are both developing cancer drugs, but they are at different points. Context has early clinical data, a narrower pipeline and cash that it expects to last into late 2027. Silexion is starting a larger trial with far less cash. The most useful points to watch for each are the evidence behind its claims, the cash available to reach the next data readout, and changes in share count.